Acitretin (
Soriatane(R)) is an aromatic retinoïd (
carboxylic acid metabolite of
etretinate).
Acitretin has a terminal elimination half-life of about 55 to 60 hours. However, concomitant intake of alcohol induces transformation to
etretinate (lipophilic
ester) which has a longer terminal elimination half life (84 to 168 days). Due to the teratogenic effect of
acitretin,
contraception should be used during
therapy and 2 years afterwards.
Acitretin monotherapy is effective in pustular
psoriasis and psoriatic palmo-plantar keratoderma. In the other forms of
psoriasis, combination with
phototherapy (PUVA, UVB) or topical
therapy is necessary (
calcipotriol,
corticosteroids).
Acitretin is effective in cutaneous disorders of keratinization (ichtyosis, palmo-plantar keratoderma,
Darier's disease). Severe cutaneous forms of
lichen planus were recently recognized as indications of
acitretin treatment; 35 to 40 mg daily is the mean effective dosage in adults (0.5 mg/kg/j in children).
Acitretin was shown effective in preventing the development of new skin
carcinomas in predisposed patients (
Xeroderma pigmentosum, immunosupression).
Acitretin is a potent
teratogen. Mucocutaneous side effects are varied (
cheilitis, dry mucosae, xerosis, palmo-plantar peeling,
hair loss.), dose-dependent and reversible.
Biological side-effects consist principally in elevations of
transaminases (5 to 8% of patients). Acute hepatotoxic reactions are rare.
Hyperlipidemia is another side-effect commonly observed. Bony changes (ligament calcifications,
osteoporosis) have been reported with various incidence. In children, growth and development have to be monitored. Combination of
acitretin with potentially hepatotoxic molecules (
methotrexate) is contraindicated, as is combination with cyclines (risk of
intracranial hypertension).